Watchlist Price Alert

Cytek Biosciences Inc. (CTKB)

NASDAQ: CTKB · Real-Time Price · USD

2.42

-0.03 (-1.22%)

At close: May 23, 2025, 3:59 PM

2.42

0.21%

After-hours: May 23, 2025, 05:32 PM EDT

-1.22% (1D)

Bid	2.3
Market Cap	305.88M
Revenue (ttm)	197.05M
Net Income (ttm)	-11.25M
EPS (ttm)	-0.09
PE Ratio (ttm)	-26.83
Forward PE	-49.5
Analyst	Buy

Ask	2.62
Volume	769,104
Avg. Volume (20D)	880,339
Open	2.41
Previous Close	2.45
Day's Range	2.37 - 2.46
52-Week Range	2.37 - 7.63
Beta	1.42

About CTKB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CTKB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CTKB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-22.69%

Cytek Biosciences shares are trading lower after t... Unlock content with Pro Subscription

2 months ago

-6.65%

Cytek Biosciences shares are trading lower after the company reported worse-than-expected Q4 revenue results and issued FY25 revenue guidance below estimates.

News

1 week ago · seekingalpha.com

Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participa...

2 weeks ago · zacks.com

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.

2 weeks ago · seekingalpha.com

Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?

The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109.37%. Cytek has reported net losses due to its growth strategy. In fact, in...

3 weeks ago · seekingalpha.com

Why Cytek Biosciences Should Beat Q1 Earnings Expectations

There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitabi...

2 months ago · seekingalpha.com

Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Par...

2 months ago · zacks.com

Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates

Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.